Latest research on Velcade

Bortezomib (originally PS-341 and marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.

Velcade dosage

To confirm the results of microarray analysis, the expressions of miR-30b-5p and miR-30c-5p were further examined in a proteasome inhibitor PS-341 dose-dependent manner, by real-time PCR analysis (qPCR) in both HepG2 and MDA-MB-453 cells (Fig. 1B). [source, 2016]
The expression of these miRs was all upregulated dose-dependently in cells treated with PS-341, compared with the control cells. [source, 2016]
Three months later, she developed disease progression and was treated with 4 cycles of bortezomib and Velcade and low dose Dexamethasone. [source, 2015]
Mice were treated with PBS, bortezomib (Millennium Pharmaceuticals, Cambridge, MA) at the doses of 0.75 or 0.15 mg/kg (Velcade (H) and (L) groups, resp.), or etanercept (Enbrel, Wyeth Pharmaceuticals, Hampshire, UK) at the dose of 5 mg/kg in 0.1 mL by i.p. injection twice a week starting on the day of EAU induction. [source, 2015]
Three courses of intravenous bortezomib (Velcade) at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11 and oral Dexamethasone at a dose of 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12 were followed by HDM (200 mg/m2) on day −2 and intravenous bortezomib at a dose of 1.3 mg/m2 on days −5 and −2, and subsequent infusion of at least 2.0 × 106 CD34+ stem cells on day 0. [source, 2015]
We found that β1i-PEk ameliorated ongoing autoimmune demyelination better than the previously tested PS-341 (26) at an equivalent dose (Fig. 6). [source, 2015]
Six hours before bioluminescence imaging, mice were challenged with a single dose of Velcade via i.p. injection. [source, 2015]
Bortezomib (Velcade), a known proteasome inhibitor that interferes with the degradation of IkB and therefore the activation of NF-κB, dose dependently inhibited luciferase expression 4 h after LPS administration (Fig. 3A and B), lending support to the quantitative correlation between NF-κB activation and bioluminescence determination in the transient transgenic mice. [source, 2014]
The patient was started on hyper-CVAD/MA (fractionated Cyclophosphamide, vincristine, Doxorubicin, and Dexamethasone, alternating with high doses of methotrexate and Cytarabine) plus rituximab and Velcade chemotherapy protocol. [source, 2014]
Note that antitumor drug Velcade, inhibitor of proteasome ChTL activity, is applied in doses which minimize its overall-toxic action. [source, 2014]